# | Title | Journal | Year | Citations |
---|
1 | Inflammation as a central mechanism in Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 1,254 |
2 | Alzheimer's disease drug development pipeline: 2019 | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 546 |
3 | Alzheimer's disease drug development pipeline: 2018 | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 469 |
4 | Alzheimer's disease drug development pipeline: 2020 | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2020 | 353 |
5 | Alzheimer's disease drug development pipeline: 2017 | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 331 |
6 | Drug discovery and development: Role of basic biological research | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 330 |
7 | Marked gender differences in progression of mild cognitive impairment over 8 years | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2015 | 274 |
8 | Alzheimer's disease drug development pipeline: 2022 | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2022 | 271 |
9 | Alzheimer's disease drug development pipeline: 2021 | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2021 | 259 |
10 | White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 250 |
11 | Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 240 |
12 | Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 199 |
13 | Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 165 |
14 | The roles of inflammation and immune mechanisms in Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2016 | 161 |
15 | Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 161 |
16 | Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5 | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 160 |
17 | Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 154 |
18 | Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2015 | 137 |
19 | Speed of processing training results in lower risk of dementia | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 114 |
20 | First‐in‐human, double‐blind, placebo‐controlled, single‐dose escalation study of aducanumab (BIIB037) in mild‐to‐moderate Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2016 | 113 |
21 | Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 111 |
22 | The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 107 |
23 | Social interaction and cognitive decline: Results of a 7‐year community intervention | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 105 |
24 | UB‐311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 104 |
25 | Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 104 |
26 | Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 102 |
27 | The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2016 | 97 |
28 | The effects of noncoding aquaporin‐4 single‐nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 94 |
29 | Predicting mild cognitive impairment from spontaneous spoken utterances | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 94 |
30 | Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 94 |
31 | Lower brain and blood nutrient status in Alzheimer's disease: Results from meta‐analyses | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 92 |
32 | Web‐enabled conversational interactions as a method to improve cognitive functions: Results of a 6‐week randomized controlled trial | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2015 | 87 |
33 | Alzheimer's drug‐development pipeline: 2016 | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2016 | 87 |
34 | Measuring cognition and function in the preclinical stage of Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 87 |
35 | A randomized, double‐blind, placebo‐controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 83 |
36 | Is late‐onset Alzheimer's disease really a disease of midlife? | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2015 | 82 |
37 | Racial disparities and temporal trends in dementia misdiagnosis risk in the United States | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 81 |
38 | The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 80 |
39 | Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 79 |
40 | A systematic review of the use of virtual reality and its effects on cognition in individuals with neurocognitive disorders | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 79 |
41 | A randomized feasibility pilot trial of hearing treatment for reducing cognitive decline: Results from the Aging and Cognitive Health Evaluation in Elders Pilot Study | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 76 |
42 | Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 75 |
43 | Electrical brain stimulation in different variants of primary progressive aphasia: A randomized clinical trial | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 75 |
44 | A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 73 |
45 | African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 71 |
46 | Analysis of dementia in the US population using Medicare claims: Insights from linked survey and administrative claims data | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 71 |
47 | Inferior parietal transcranial direct current stimulation with training improves cognition in anomic Alzheimer's disease and frontotemporal dementia | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 70 |
48 | A randomized, single ascending dose study of intravenous BIIB092 in healthy participants | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 70 |
49 | A metabolite‐based machine learning approach to diagnose Alzheimer‐type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 70 |
50 | Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough? | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 69 |